International Journal of Science and Research (IJSR)

International Journal of Science and Research (IJSR)
Call for Papers | Fully Refereed | Open Access | Double Blind Peer Reviewed

ISSN: 2319-7064




Downloads: 16 | Views: 232 | Weekly Hits: ⮙1 | Monthly Hits: ⮙2

Case Studies | Medicine | Indonesia | Volume 12 Issue 9, September 2023 | Rating: 6.1 / 10


Challenges in the Management of Lung Adenocarcinoma in Elderly Patients: Case Report

I Nyoman Gede Witriadnyana | Putu Ayu Diah Puspita Sari [3] | Luh Dewi Rahayu


Abstract: The management of elderly lung cancer patients has many challenges in providing therapeutic regimens. Diagnosis, patient performance status, tumour stage, and molecular mutations of lung cancer are key in providing drugs to NSCLC patients with very minimal side effects compared to chemotherapy. Rapid developments in molecular biology are currently having a positive impact on the maintenance and quality of life of patients. Epidermal Growth Factor Receptor - Tyrosine Kinase Inhibitors (EGFR - TKI) molecular therapy is a targeted therapy used in lung cancer patients with positive EGFR mutations to stop cancer cell growth. Adequate screening for EGFR mutations is necessary for optimal therapy. We report a 78 - year - old male patient with a diagnosis of non - small cell lung cancer (NSCLC) of the adenocarcinoma type. The diagnosis is based on anamnesis, physical examination, supporting examinations and examination of EGFR mutations. In the EGFR mutation, positive results were obtained with the Exon 19 Dels type. The target therapy plan provided is with the first generation EGFR - TKI, namely gefitinib. But before giving targeted therapy, the patient's condition worsened.


Keywords: elderly lung cancer, therapeutic regimens, molecular mutations, EGFR - TKI targeted therapy, Lung Adenocarcinoma


Edition: Volume 12 Issue 9, September 2023,


Pages: 14 - 23


How to Download this Article?

Type Your Valid Email Address below to Receive the Article PDF Link


Verification Code will appear in 2 Seconds ... Wait

Top